Why Wait for Another Relapse to Start on a Long-acting Injectable (LAI)?

Adult patients with schizophrenia spend over a decade cycling on oral antipsychotic regimens before their first LAI regimen1

treatment cycle
  • 78% of patients want their clinician to offer a choice between a daily oral or a once-monthly LAI3†
  • 74% of those who wanted a choice would be likely to try a once-monthly LAI3‡

*From Janssen-sponsored market research, a total of 620 patient charts were collected from 161 healthcare providers (HCPs) from August 22 through September 12, 2016. Key screening criteria included: must have seen at least 30 individual patients with schizophrenia during the past 3 months, must have treated at least 1 patient with 1 of the 10 specified antipsychotics in the past 3 months, and should have been in practice for a minimum of 2 and a maximum of 35 years.

†Based on results from market research using an online survey with randomly selected psychiatrists (n=200) and schizophrenia patients (n=300). Market research conducted by GfK on behalf of Janssen Pharmaceuticals, Inc.3

‡Of the 78% (n=234) of patients who had identified themselves as wanting the choice between a monthly injectable long-acting therapy or a daily oral, 74% (n=173) would be likely to try a monthly long-acting injectable antipsychotic.

Do You See Patients Like This in Your Practice?

Clinically unstable or history of relapse

  • Struggles to take daily medication consistently
  • Currently has, or has recently had, inadequately controlled symptoms
  • Accepts the need to take medication
  • Tolerates oral risperidone or paliperidone
is emeka alpha is

New Clinical Guidance Supports Earlier Use of LAIs in Adults With Schizophrenia4

National Council for behavioral health

The National Council for Behavioral Health supports the safe and effective use of LAIs by encouraging mental healthcare professionals to utilize LAIs as an earlier treatment option rather than using them only after multiple negative outcomes such as failed oral medications, multiple relapses, or hospitalizations.

With INVEGA SUSTENNA® You Can be Confident Patients Receive 1 Month of Medication5*


*After both initiation doses.

†Both initiation doses must be delivered in the deltoid muscle.

  • INVEGA SUSTENNA® initiation regimen allowed patients to stay in a median exposure window of 6 mg-12 mg extended-release oral paliperidone
  • Correlation to clinical effect has not been established
  • No oral supplementation required during initiation
  • Due to the difference in median pharmacokinetic profiles between INVEGA SUSTENNA® and oral INVEGA® (paliperidone) tablets, use caution when directly comparing their pharmacokinetic properties5

The Formulation of INVEGA SUSTENNA® Allows for Gradual Release of the Medicine

one month

INVEGA SUSTENNA® includes smaller particles that dissolve to achieve rapid plasma levels* without oral supplementation during the initiation window, and larger particles that continue to dissolve to maintain sustained plasma levels for over 1 month.5,6,7


*After both initiation doses.

References: 1. Data on file. Chart Review. Janssen Pharmaceuticals, Inc., Titusville, NJ. 2016. 2. National Alliance on Mental Illness. What is Schizophrenia. https://www.nami.org/Learn-More/Mental-Health-Conditions/ Schizophrenia. Published November 15, 2013. Accessed June 6, 2019. 3. Data on file. Attitudinal-Disconnect Claim Study. Janssen Products, L.P., Titusville, NJ. 2012. 4. National Council of Behavioral Health. Guide to Long-acting Medications for Providers and Organizations. https://www.thenationalcouncil.org/topics/long-acting-medications/. Published June 5, 2019. Accessed June 5, 2019. 5. INVEGA SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; January 2019. 6. Data on File. CSR. Janssen Pharmaceuticals, Inc., Titusville, NJ. 2003. 7. Bishara D, Taylor D. Paliperidone palmitate–a new long-acting injectable for schizophrenia. Br J Clin Pharmacol. 2011;3:75-78.